Shalini L Kulasingam

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral
    Shalini L Kulasingam
    Department of Epidemiology, University of Washington, Seattle, WA, USA
    JAMA 288:1749-57. 2002
  2. ncbi Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS)
    Shalini L Kulasingam
    Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA
    J Natl Cancer Inst 98:92-100. 2006
  3. ncbi Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests
    Shalini L Kulasingam
    Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, USA
    Obstet Gynecol 107:321-8. 2006
  4. ncbi Potential health and economic impact of adding a human papillomavirus vaccine to screening programs
    Shalini L Kulasingam
    Department of Obstetrics and Gynecology and Center for Clinical Health Policy Research, Duke University, Durham, NC 27705, USA
    JAMA 290:781-9. 2003
  5. ncbi A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program
    Shalini Kulasingam
    Duke University, Center for Clinical Health Policy Research, Durham, NC 27710, USA
    Sex Health 4:165-75. 2007
  6. ncbi Lower observed versus expected (based on U.S. age and gender specific rates) survival in patients treated for near-fatal ventricular arrhythmias
    Shalini L Kulasingam
    AVID Clinical Trial Center and University of Washington, Seattle, Washington, USA
    Pacing Clin Electrophysiol 27:230-4. 2004
  7. ncbi Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S
    Shalini L Kulasingam
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27705, United States
    Vaccine 25:8110-3. 2007
  8. ncbi Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States
    Janet G Baseman
    Department of Epidemiology, University of Washington, Seattle, WA, USA
    Am J Obstet Gynecol 199:26.e1-8. 2008
  9. ncbi Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia
    Tiffany G Harris
    Department of Epidemiology, University of Washington, Seattle, WA, USA
    Am J Epidemiol 159:834-42. 2004
  10. ncbi Risk of cervical cancer associated with extending the interval between cervical-cancer screenings
    George F Sawaya
    Department of Obstetrics, Gynecology, and Reproductive Sciences, Department of Veterans Affairs and University of California, San Francisco, San Francisco, USA
    N Engl J Med 349:1501-9. 2003

Research Grants

  1. An interdisciplinary use of models for cancer prevention
    Shalini Kulasingam; Fiscal Year: 2007

Detail Information

Publications27

  1. ncbi Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral
    Shalini L Kulasingam
    Department of Epidemiology, University of Washington, Seattle, WA, USA
    JAMA 288:1749-57. 2002
    ..In some settings, particularly where screening intervals are long or haphazard, screening for HPV DNA may be a reasonable alternative to cytology-based screening of reproductive-age women...
  2. ncbi Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS)
    Shalini L Kulasingam
    Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA
    J Natl Cancer Inst 98:92-100. 2006
    ..We conducted a cost-effectiveness analysis of the ALTS trial to determine whether HPV DNA testing is a cost-effective alternative to immediate colposcopy or conservative management with up to three cytology examinations...
  3. ncbi Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests
    Shalini L Kulasingam
    Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, USA
    Obstet Gynecol 107:321-8. 2006
    ..We estimated the cost-effectiveness of screening women with 3 or more prior normal tests compared with screening those with no prior tests...
  4. ncbi Potential health and economic impact of adding a human papillomavirus vaccine to screening programs
    Shalini L Kulasingam
    Department of Obstetrics and Gynecology and Center for Clinical Health Policy Research, Duke University, Durham, NC 27705, USA
    JAMA 290:781-9. 2003
    ..Recently published results suggest that effective vaccines against cervical cancer-associated human papillomavirus (HPV) may become available within the next decade...
  5. ncbi A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program
    Shalini Kulasingam
    Duke University, Center for Clinical Health Policy Research, Durham, NC 27710, USA
    Sex Health 4:165-75. 2007
    ..The cost-effectiveness of adding a human papillomavirus (HPV) vaccine to the Australian National Cervical Screening Program compared to screening alone was examined...
  6. ncbi Lower observed versus expected (based on U.S. age and gender specific rates) survival in patients treated for near-fatal ventricular arrhythmias
    Shalini L Kulasingam
    AVID Clinical Trial Center and University of Washington, Seattle, Washington, USA
    Pacing Clin Electrophysiol 27:230-4. 2004
    ....
  7. ncbi Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S
    Shalini L Kulasingam
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27705, United States
    Vaccine 25:8110-3. 2007
    ..These results highlight the importance of educating women to ensure continued screening, as well as the need to consider new approaches to screening in the era of vaccination...
  8. ncbi Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States
    Janet G Baseman
    Department of Epidemiology, University of Washington, Seattle, WA, USA
    Am J Obstet Gynecol 199:26.e1-8. 2008
    ....
  9. ncbi Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia
    Tiffany G Harris
    Department of Epidemiology, University of Washington, Seattle, WA, USA
    Am J Epidemiol 159:834-42. 2004
    ..Since smoking was associated with both CIN1 and >/= CIN2-3, cigarette by-products may affect the early evolution of HPV-related lesions, possibly by increasing the rate of cell turnover...
  10. ncbi Risk of cervical cancer associated with extending the interval between cervical-cancer screenings
    George F Sawaya
    Department of Obstetrics, Gynecology, and Reproductive Sciences, Department of Veterans Affairs and University of California, San Francisco, San Francisco, USA
    N Engl J Med 349:1501-9. 2003
    ....
  11. ncbi Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection
    Tiffany G Harris
    Department of Epidemiology, University of Washington School of Public Health and Community Medicine, Seattle, WA, USA
    Am J Obstet Gynecol 200:489.e1-8. 2009
    ..The objective of the study was to examine the relationship of depot-medroxyprogesterone acetate (DMPA) and combined oral contraceptive (COC) use with cervical intraepithelial neoplasia (CIN)...
  12. ncbi Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples
    Akhila Balasubramanian
    Department of Epidemiology, University of Washington, Seattle, WA, USA
    J Low Genit Tract Dis 14:185-95. 2010
    ..Estimate the accuracy and cost-effectiveness of cervical cancer screening strategies based on high-risk human papillomavirus (HPV) DNA testing of self-collected vaginal samples...
  13. ncbi Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis
    Shalini L Kulasingam
    Duke University, Center for Clinical Health Policy Research, Durham, NC, USA
    BMC Med 7:69. 2009
    ..We determined the potential cost-effectiveness of including human papillomavirus tests for cervical cancer screening for Canada and three provinces: Alberta, Newfoundland and Ontario...
  14. ncbi Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 107:211-8. 2007
    ..We wished to compare the cost-effectiveness of three chemotherapy regimens for treatment of recurrent platinum-sensitive ovarian cancer...
  15. ncbi When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision analysis
    Shalini L Kulasingam
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham NC, USA
    Value Health 6:542-50. 2003
    ..Functional neuroimaging, including positron emission tomography (PET), has been proposed for use in diagnosing Alzheimer's disease-related dementia (AD)...
  16. ncbi Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham NC 27710, USA
    Gynecol Oncol 113:216-20. 2009
    ..1) To define a set of health state descriptions related to screening, diagnosis, prognosis, and toxicities relevant to ovarian cancer; (2) To derive a set of quality of life-related utilities to be used for cost-effectiveness analyses...
  17. ncbi Dissemination of Evidence-based Practice Center reports
    David B Matchar
    Duke University, Durham, North Carolina 27705, USA
    Ann Intern Med 142:1120-5. 2005
    ....
  18. ncbi Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 117:545-53. 2011
    ..The objective of the current study was to estimate the impact of a 2-phenotype paradigm of epithelial ovarian cancer on the mortality reduction achievable using available screening technologies...
  19. ncbi Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study
    Laura J Havrilesky
    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 26:4144-50. 2008
    ..To determine the cost effectiveness of intraperitoneal versus intravenous regimens for adjuvant treatment of optimally resected stage III ovarian cancer...
  20. ncbi Screening for cervical cancer: a modeling study for the US Preventive Services Task Force
    Shalini L Kulasingam
    Minnesota Evidence based Practice Center, University of Minnesota, Minneapolis, MN 55454, USA
    J Low Genit Tract Dis 17:193-202. 2013
    ..for cervical cancer end; and (3) how do the benefits and potential harms of screening strategies that use human papillomavirus DNA testing in conjunction with cytology (cotesting) compare with those strategies that use cytology only?..
  21. ncbi FDG-PET for management of cervical and ovarian cancer
    Laura J Havrilesky
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 97:183-91. 2005
    ..To assess the diagnostic performance of Positron Emission Tomography using fluorodeoxyglucose (FDG-PET) in comparison to conventional imaging modalities in the assessment of patients with cervical and ovarian cancer...
  22. ncbi Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
    Laura J Havrilesky
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Gynecol Oncol 111:179-87. 2008
    ..We wished to estimate the clinical impact and cost-effectiveness of potential screening strategies for ovarian cancer using population-specific data...
  23. ncbi Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness
    Joy Melnikow
    Department of Economics, Center for Healthcare Policy and Research, University of California, Davis, California 95817, USA
    Obstet Gynecol 116:1158-70. 2010
    ..To estimate outcomes and costs of surveillance strategies after treatment for high-grade cervical intraepithelial neoplasia (CIN)...
  24. ncbi Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis
    Elizabeth L Jewell
    Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Gynecol Oncol 107:532-40. 2007
    ..To estimate the relative cost-effectiveness of treatments for patients with FIGO stage IB2 cervical cancer and no evidence of metastasis as determined by combination of positron emission tomography/computed tomography (PET/CT)...
  25. ncbi Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening
    Michael A Bidus
    Division of Gynecologic Oncology and the United States Military Cancer Institute, Walter Reed Army Medical Center, Washington, DC 20307, USA
    Obstet Gynecol 107:997-1005. 2006
    ..S. Army, cervix cancer screening performed with liquid-based cytology and reflex HPV testing of atypical squamous cells of undetermined significance performed every 2 years is cost-effective, especially when indirect costs are considered...
  26. ncbi Liquid-based Papanicolaou smears without a transformation zone component: should clinicians worry?
    Atar Baer
    Department of Epidemiology, University of Washington, Seattle, Washington 98103, USA
    Obstet Gynecol 99:1053-9. 2002
    ..To evaluate whether ThinPrep smears without versus those with a transformation zone component were more likely to have falsely negative cytology findings...
  27. ncbi Linking dementia research to policy: an example using fluorodeoxyglucose positron emission tomography for the diagnosis of Alzheimer's dementia and mild cognitive impairment
    Shalini L Kulasingam
    Am J Alzheimers Dis Other Demen 21:73-8. 2006

Research Grants1

  1. An interdisciplinary use of models for cancer prevention
    Shalini Kulasingam; Fiscal Year: 2007
    ..For a rational shift in public health practice, we will need an evaluation of the new primary and secondary prevention methods; part of this evaluation will involve cost-effectiveness analyses using sophisticated simulation models. ..